Nov 2016 - YProtech exhibiting at Genesis 2016

We will be exhibiting at Genesis 2016 on 1st December, London. The theme of Genesis 2016 is The Science, Technology and Business of 21st Century Biomedical Innovation. This reflects that the conference agenda will showcase success in the application of biomedical research, innovative technologies and leading edge business strategies in order to deliver effective benefit to patients globally. YProtech will be part of the Life Sciences in the Northern Powerhouse stand. Find out more here.

Nov 2016 - EPSRC Grant for Organic Synthesis with the University of York

Professor Peter O’Brien and Dr Peter Karadakov, together with academic partner Professor Jacques Maddaluno (Rouen) and industrial partners AstraZeneca and YProtech, have been awarded a new Engineering and Physical Sciences Research Council (EPSRC) research grant. The grant is entitled “C–H Functionalisation of Cyclic Ethers: New Routes to 3-D Fragments, Scaffolds and Pharmaceuticals” and will support a post-doctoral researcher for 3.5 years. Additional information can be found here.

Oct 2016 - YProtech secures successful fundraise

YProtech have secured a successful fundraise for specialist chemical technology services company arranged by Acceleris Capital. YProtech have raised £0.25m from a syndicate including Catapult Ventures, existing shareholders and new HNW individuals. The funds are to be used to launch a high-potency facility at YProtech’s Alderley Science Park base. Tony Flinn has also been appointed to the Board as a new Non-Executive Director. To read more click here.

Sept 2016 - YProtech obtains Controlled Drugs Licence

YProtech has obtained Home Office approval under the Misuse of Drugs Act 1971 to Possess, Supply and Produce Controlled Drugs including all Schedule 1, Schedule2, Schedule 3 and Schedule 4 drugs. The licence also approves YProtech to Supply and Produce Schedule 5 drugs.

With this licence, and by following the accompanying procedures and protocols, YProtech can now carry out research projects for clients that incorporate controlled substances such as phenylethylamines. This both broadens YProtech's services offering and strengthens our capabilities.

If you have any chemistry challenges incorporating controlled substances we can provide you with a competitive proposal.

Sept 2016 - New Products: Tomaymycin (CAS 35050-55-6) and Tomaymycin DM (CAS 945490-09-5) Available

YProtech are now offering the pyrrolobenzadiazapine cytotoxin natural products Tomaymycin (CAS 35050-55-6) and Tomaymycin DM (CAS 945490-09-5). Manufactured in the UK, these toxins are available to ship directly from YProtech. Please send your enquiries to This email address is being protected from spambots. You need JavaScript enabled to view it..